AI assistant
X4 Pharmaceuticals, Inc — Director's Dealing 2017
Nov 15, 2017
34355_dirs_2017-11-15_13847a60-164e-4443-8dca-1a6e10084491.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15
Reporting Person: Nagy Eszter (Chief Scientific Officer, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 273464 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $1.85 | 2023-04-18 | Common Stock (71491) | Direct | |
| Stock Option (right to buy) | $9.39 | 2026-07-19 | Common Stock (29299) | Direct | |
| Stock Option (right to buy) | $4.00 | 2027-06-18 | Common Stock (43949) | Direct |
Footnotes
F1: This option fully vested on September 1, 2014.
F2: This option was granted on July 20, 2016 and immediately vested as to 40% of the original 29,299 shares underlying the option, with 3.4483% of the original 29,299 shares vesting monthly thereafter until the date that is 29 months following the grant date, subject to continued service.
F3: This option was granted on June 19, 2017 and vests over four years, with 25% of the original 43,949 shares underlying the option vesting on June 19, 2018 and 2.0833% of the original 43,949 shares vesting monthly thereafter, subject to continued service.